Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Cholic Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN116103254B reveals stable enzyme mutants for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel synthesis of 3 beta-ursodesoxycholic acid via selective esterification and stereoselective reduction. High yield, mild conditions, cost-effective manufacturing solution.
Patent CN102660755B reveals electroreduction method for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN113135971A details a high-yield synthesis of carbon-losing cholestanal from duck cholic acid, offering a cost-effective route for API intermediates.
Novel patent CN112724189B details waste-to-value synthesis enhancing supply chain reliability and cost efficiency for global pharmaceutical intermediate procurement strategies.
Patent CN105541953B details a recrystallization method achieving high purity without column chromatography, offering significant cost reduction in API manufacturing and supply chain reliability.
Patent CN113736842B reveals high-purity TUDCA production via multi-cell catalysis. Offers cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Patent CN106701882A details a novel chemo-enzymatic route for UDCA production offering high purity and scalable manufacturing capabilities for global pharmaceutical supply chains.
Patent CN109134577B reveals a novel 4-step synthesis for lithocholic acid isomers, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN107200763B reveals a novel two-step synthesis for lithocholic acid. This method offers high purity and scalable production for pharmaceutical supply chains.
Patent CN103319560A details a high-yield UDCA synthesis from CDCA using NBS oxidation and Luche reduction, offering cost reduction in API manufacturing and reliable pharmaceutical intermediates supply.
Patent CN115716857B details a novel aqueous purification route for lithocholic acid achieving over 99 percent purity. This method significantly reduces impurities and enhances supply chain reliability for pharmaceutical manufacturers.
Novel patent CN107245089A offers cost-effective Obeticholic Acid synthesis. Enhanced supply chain reliability and scalable manufacturing for global pharmaceutical partners.
Novel borate catalysis method for TUDCA synthesis ensures high purity and reduced cost. Scalable process for pharmaceutical intermediates supply chain optimization and reliability.
Patent CN112724189A details a novel semi-synthetic route for Chenodeoxycholic Acid from waste bile acids, offering significant cost reduction and supply chain stability for API manufacturers.
Patent CN110423261B reveals a novel synthesis route for 7-ketolithocholic acid from hyocholic acid, offering high purity and significant cost reduction in bile acid manufacturing.
Patent CN114940964B reveals efficient UDCA production. Reduced costs and high purity for pharmaceutical supply chains.
Patent CN115011661B reveals enzymatic synthesis for 3 beta-ursodeoxycholic acid. High purity, mild conditions, scalable supply chain solutions for pharma.
Patent CN106046095A reveals mild synthesis route. Reduces LDA use significantly. Reliable supply chain partner for commercial scale-up and high purity API intermediates.
Patent CN105566429B details a novel one-step reduction for high-purity amorphous Obeticholic Acid Form 1, offering significant cost and supply chain advantages.